Hubei Biocause Pharmaceutical (000627) — Strategic Asset Allocation Index
Hubei Biocause Pharmaceutical (000627) has a Strategic Asset Allocation Index of 368.8% as of September 2024. Strategic assets (PP&E of CN¥- plus long-term investments of CN¥132.77 Billion) total CN¥132.77 Billion, measured against net assets of CN¥36.00 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Hubei Biocause Pharmaceutical Strategic Asset Allocation Index (2000–2023)
This chart shows how Hubei Biocause Pharmaceutical's Strategic Asset Allocation Index has evolved across 24 annual periods from 2000 to 2023. As of September 2024, the index stands at 368.8%, representing strategic assets of CN¥132.77 Billion against net assets of CN¥36.00 Billion CNY. Explore cash efficiency ratio of Hubei Biocause Pharmaceutical to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Hubei Biocause Pharmaceutical (2000–2023)
The table below presents the year-by-year Strategic Asset Allocation Index for Hubei Biocause Pharmaceutical from 2000 to 2023, covering 24 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Hubei Biocause Pharmaceutical market capitalisation.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2023 | 408.8% | CN¥137.49 Billion | CN¥- | CN¥137.49 Billion | CN¥33.63 Billion | ▲ +21.8 pp |
| 2022 | 387.0% | CN¥133.91 Billion | CN¥- | CN¥133.91 Billion | CN¥34.60 Billion | ▲ +66.8 pp |
| 2021 | 320.2% | CN¥120.00 Billion | CN¥830.33 Million | CN¥119.17 Billion | CN¥37.47 Billion | ▲ +282.7 pp |
| 2020 | 37.5% | CN¥12.97 Billion | CN¥580.44 Million | CN¥12.39 Billion | CN¥34.59 Billion | ▼ -2.3 pp |
| 2019 | 39.8% | CN¥13.66 Billion | CN¥567.17 Million | CN¥13.10 Billion | CN¥34.35 Billion | ▼ -259.0 pp |
| 2018 | 298.8% | CN¥77.73 Billion | CN¥770.87 Million | CN¥76.96 Billion | CN¥26.01 Billion | ▲ +63.6 pp |
| 2017 | 235.2% | CN¥62.82 Billion | CN¥700.40 Million | CN¥62.12 Billion | CN¥26.70 Billion | ▼ -81.7 pp |
| 2016 | 316.9% | CN¥64.64 Billion | CN¥587.41 Million | CN¥64.05 Billion | CN¥20.40 Billion | ▲ +233.1 pp |
| 2015 | 83.8% | CN¥1.50 Billion | CN¥334.69 Million | CN¥1.16 Billion | CN¥1.78 Billion | ▲ +53.3 pp |
| 2014 | 30.5% | CN¥454.18 Million | CN¥454.18 Million | CN¥- | CN¥1.49 Billion | ▼ -36.9 pp |
| 2013 | 67.3% | CN¥967.21 Million | CN¥967.21 Million | CN¥- | CN¥1.44 Billion | ▲ +5.1 pp |
| 2012 | 62.2% | CN¥956.70 Million | CN¥956.70 Million | CN¥- | CN¥1.54 Billion | ▲ +4.8 pp |
| 2011 | 57.4% | CN¥811.97 Million | CN¥811.97 Million | CN¥- | CN¥1.41 Billion | ▲ +0.6 pp |
| 2010 | 56.8% | CN¥909.50 Million | CN¥909.50 Million | CN¥- | CN¥1.60 Billion | ▼ -15.0 pp |
| 2009 | 71.8% | CN¥1.13 Billion | CN¥1.13 Billion | CN¥- | CN¥1.57 Billion | ▲ +12.6 pp |
| 2008 | 59.2% | CN¥895.44 Million | CN¥895.44 Million | CN¥- | CN¥1.51 Billion | ▼ -14.1 pp |
| 2007 | 73.3% | CN¥634.63 Million | CN¥634.63 Million | CN¥- | CN¥866.03 Million | ▼ -3.7 pp |
| 2006 | 77.0% | CN¥557.14 Million | CN¥557.14 Million | CN¥- | CN¥723.71 Million | ▲ +10.7 pp |
| 2005 | 66.3% | CN¥484.56 Million | CN¥484.56 Million | CN¥- | CN¥731.23 Million | ▲ +18.8 pp |
| 2004 | 47.4% | CN¥343.27 Million | CN¥343.27 Million | CN¥- | CN¥723.91 Million | ▲ +0.3 pp |
| 2003 | 47.1% | CN¥338.44 Million | CN¥338.44 Million | CN¥- | CN¥718.75 Million | ▲ +5.1 pp |
| 2002 | 42.0% | CN¥322.21 Million | CN¥322.21 Million | CN¥- | CN¥768.02 Million | ▲ +7.5 pp |
| 2001 | 34.5% | CN¥262.88 Million | CN¥262.88 Million | CN¥- | CN¥762.99 Million | ▼ -25.3 pp |
| 2000 | 59.7% | CN¥355.08 Million | CN¥355.08 Million | CN¥- | CN¥594.52 Million | — |